TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Rhea-AI Summary

TG Therapeutics (NASDAQ: TGTX) announced that CEO Michael S. Weiss will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, held at the Loews Miami Beach Hotel, from June 10-13, 2024.

Weiss is scheduled for a fireside chat on June 11, 2024, at 1:20 PM ET. A live webcast will be available on the company's Investors & Media section.

Positive

• TG Therapeutics' participation in the prestigious Goldman Sachs conference could enhance investor visibility.
• CEO Michael S. Weiss's engagement at the event may provide insights into the company's strategic direction and upcoming milestones.

Negative

• No new clinical or financial data will be presented at the event, potentially limiting immediate investor benefits.
• The announcement lacks concrete updates on product pipelines or financial performance, which may not meet investor expectations.

Fireside chat scheduled for Tuesday, June 11, 2024, at 1:20 PM ET

NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 45^th Annual Global Healthcare Conference, being held at the Loews Miami Beach Hotel, Miami Beach, FL on June 10-13, 2024. The fireside chat is scheduled to take place on Tuesday, June 11, 2024, at 1:20 PM ET.

A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.

ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.

BRIUMVI® is a registered trademark of TG Therapeutics, Inc.

CONTACT:

Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6

FAQ

When is TG Therapeutics participating in the Goldman Sachs conference?

TG Therapeutics will participate from June 10-13, 2024, specifically on June 11 at 1:20 PM ET for a fireside chat.

Where is the Goldman Sachs 45th Annual Global Healthcare Conference held?

The conference is held at the Loews Miami Beach Hotel, Miami Beach, FL.

How can I watch the TG Therapeutics fireside chat?

A live webcast of the fireside chat will be available on the TG Therapeutics website under the Investors & Media section.

What is the stock symbol for TG Therapeutics?

The stock symbol for TG Therapeutics is TGTX.

Who will represent TG Therapeutics at the Goldman Sachs conference?

Michael S. Weiss, the CEO of TG Therapeutics, will represent the company.